Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic umbilical cord blood-derived CAR-T
- Development stage
- Phase 1
- Lead developer
- General Hospital of Western Theater Command of PLA
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
This is an investigational allogeneic chimeric antigen receptor T-cell (CAR-T) therapy derived from healthy donor umbilical cord blood (UCB). Developed by The General Hospital of Western Theater Command, the therapy targets the CD19 antigen, a surface protein expressed on B-cells. Unlike autologous CAR-T therapies that require patient-specific leukapheresis and manufacturing, this allogeneic approach utilizes T-cells from umbilical cord blood units, allowing for an "off-the-shelf" product. Preclinical data indicate that these UCB-derived CAR-T cells exhibit low immunogenicity and a reduced potential for graft-versus-host disease (GvHD) while maintaining potent anti-tumor efficacy. It is currently being evaluated in an Early Phase 1 clinical trial for safety and efficacy in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL).
- Other names
- allogeneic umbilical cord blood-derived chimeric antigen receptor T-cellumbilical cord blood-derived CAR-TUCB-derived CAR-T
02
Targets
Beyond the preview
Go deeper on allogeneic umbilical cord blood-derived CAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic umbilical cord blood-derived CAR-T.